BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Esquivias P, Morandeira A, Escartín A, Cebrián C, Santander S, Esteva F, García-González MA, Ortego J, Lanas A, Piazuelo E. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. World J Gastroenterol 2012; 18(35): 4866-4874 [PMID: 23002358 DOI: 10.3748/wjg.v18.i35.4866]
URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4866.htm
Number Citing Articles
1
Jennifer L. Schneider, Wei K. Zhao, Douglas A. Corley. Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Barrett’s EsophagusDigestive Diseases and Sciences 2015; 60(2): 436 doi: 10.1007/s10620-014-3349-2
2
Christina L. Greene, Stephanie G. Worrell, Tom R. DeMeester. Rat Reflux Model of Esophageal Cancer and Its Implication in Human DiseaseAnnals of Surgery 2015; 262(6): 910 doi: 10.1097/SLA.0000000000001207
3
PAULA ESQUIVIAS, CARMELO CEBRIÁN, ANTONIO MORANDEIRA, SONIA SANTANDER, JAVIER ORTEGO, MARÍA ASUNCIÓN GARCÍA-GONZÁLEZ, ANGEL LANAS, ELENA PIAZUELO. Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental modelOncology Reports 2014; 31(6): 2785 doi: 10.3892/or.2014.3137
4
Alessandra Pannunzio, Mauro Coluccia. Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry LiteraturePharmaceuticals 2018; 11(4): 101 doi: 10.3390/ph11040101
5
Jennifer L. Schneider, Douglas A. Corley. A review of the epidemiology of Barrett's oesophagus and oesophageal adenocarcinomaBest Practice & Research Clinical Gastroenterology 2015; 29(1): 29 doi: 10.1016/j.bpg.2014.11.008
6
Giselle Hevia, Isabel Pablos, Marilyn Clavell, Judith Raymond, Mayrel Labrada, Luis E. Fernández. Cyclooxygenase Inhibition in Cancer Immunotherapy: Combination of Indomethacin with Cancer Vaccines Is Not Always BeneficialJournal of Cancer Therapy 2017; 8(02): 188 doi: 10.4236/jct.2017.82016